Jump to main content
Jump to site search


Gold glyconanoparticles coupled to listeriolysin O 91–99 peptide serve as adjuvant therapy against melanoma

Author affiliations

Abstract

Dendritic cell-based (DC-based) vaccines are promising immunotherapies for cancer. However, several factors, such as the lack of efficient targeted delivery and the sources and types of DCs, have limited the efficacy of DCs and their clinical potential. We propose an alternative nanotechnology-based vaccine platform with antibacterial prophylactic abilities that uses gold glyconanoparticles coupled to listeriolysin O 91–99 peptide (GNP-LLO91–99), which acts as a novel adjuvant for cancer therapy. GNP-LLO91–99, when used to vaccinate mice, exhibited dual antitumour activities, namely, the inhibition of tumour migration and growth and adjuvant activity for recruiting and activating DCs, including those from melanoma patients. GNP-LLO91–99 nanoparticles caused tumour apoptosis and induced antigen- and melanoma-specific cytotoxic Th1 responses (P ≤ 0.5). We propose this adjuvant nanotherapy for preventing the progression of the first stages of melanoma.

Graphical abstract: Gold glyconanoparticles coupled to listeriolysin O 91–99 peptide serve as adjuvant therapy against melanoma

Back to tab navigation

Supplementary files

Publication details

The article was received on 07 Apr 2017, accepted on 27 Jun 2017 and first published on 28 Jun 2017


Article type: Paper
DOI: 10.1039/C7NR02494K
Citation: Nanoscale, 2017, Advance Article
  •   Request permissions

    Gold glyconanoparticles coupled to listeriolysin O 91–99 peptide serve as adjuvant therapy against melanoma

    R. Calderon-Gonzalez, H. Terán-Navarro, I. García, M. Marradi, D. Salcines-Cuevas, S. Yañez-Diaz, A. Solis-Angulo, E. Frande-Cabanes, M. C. Fariñas, A. Garcia-Castaño, J. Gomez-Roman, S. Penades, F. Rivera, J. Freire and C. Álvarez-Domínguez, Nanoscale, 2017, Advance Article , DOI: 10.1039/C7NR02494K

Search articles by author

Spotlight

Advertisements